Matthew K. Fust, Director at Ultragenyx Pharmaceutical, holds 20.20K shares in Ultragenyx Pharmaceutical (Ticker: RARE), holds 20.10K shares in Neumora Therapeutics, Inc. (Ticker: NMRA), holds 21.94K shares in Crinetics Pharmaceuticals (Ticker: CRNX).
What is the percentage of profitable transactions made by Matthew K. Fust?
The percentage of profitable transactions made by Matthew K. Fust is 58%.
What is the average return per transaction made by Matthew K. Fust?
The average return per transaction made by Matthew K. Fust is 19.80%.
What stocks does Matthew K. Fust hold?
Matthew K. Fust holds: RARE, CRNX, NMRA, DERM, ~DERM, MGNX, ATRA, JAZZ, ONXX stocks.
What was Matthew K. Fust’s latest transaction?
Matthew K. Fust latest transaction was an Uninformative Buy of ―.
What was Matthew K. Fust's most profitable transaction?
Matthew K. Fust’s most profitable transaction was an Informative Buy of ~DERM stock on November 26, 2014. The return on the trade was 69.50%.
What is Matthew K. Fust's role in Ultragenyx Pharmaceutical?
Matthew K. Fust's role in Ultragenyx Pharmaceutical is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.